Lisa Beilke

Lisa Beilke

Auto-generated profile, based on publicly available information

Lisa Beilke

Toxicology Solutions, Inc., Marana, AZ, United States

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2009 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
PDF file
LBLisa D. Beilke
Lisa D. Beilke
LALauren Aleksunes
Lauren Aleksunes
RHRicky D. Holland
Ricky D. Holland
DBDavid Besselsen
David Besselsen
RBRick D. Beger
Rick D. Beger
NCNathan J. Cherrington
Nathan J. Cherrington
Pharmacological activation of the constitutive androstane receptor (CAR) protects the liver during cholestasis. The current study evaluates how activation of CAR influences genes involved in bile acid biosynthesis as a mechanism of hepatoprotection during bile acid-induced liver injury. CAR activators phenobarbital (PB) and 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) or corn oil (CO) were administered to C57BL/6 wild-type (WT) and CAR knockout (CAR-null) mice before and during induction of intrahepatic cholestasis using the secondary bile acid, lithocholic acid (LCA). In LCA-treated WT and all the CAR-null groups (excluding controls), histology revealed severe multifocal necrosis. This pathology was absent in WT mice pretreated with PB and TCPOBOP, indicating CAR-dependent hepatoprotection. Decreases in total hepatic bile acids and hepatic monohydroxy, dihydroxy, and trihydroxy bile acids in PB- and TCPOBOP-pretreated WT mice correlated with hepatoprotection. In comparison, concentrations of monohydroxylated and dihydroxylated bile acids were increased in all the treated CAR-null mice compared with CO controls. Along with several other enzymes (Cyp7b1, Cyp27a1, Cyp39a1), Cyp8b1 expression was increased in hepatoprotected mice, which could be suggestive of a shift in the bile acid biosynthesis pathway toward the formation of less toxic bile acids. In CAR-null mice, these changes in gene expression were not different among treatment groups. These results suggest CAR mediates a shift in bile acid biosynthesis toward the formation of less toxic bile acids, as well as a decrease in hepatic bile acid concentrations. We propose that these combined CAR-mediated effects may contribute to the hepatoprotection observed during LCA-induced liver injury.

13 September 2021 in Computational Toxicology
Verified
Journal Article
Closed access
ABArianna Bassan
Arianna Bassan
VAVinicius M. Alves
Vinicius M. Alves
AAAlexander Amberg
Alexander Amberg
LALennart T. Anger
Lennart T. Anger
LBLisa Beilke
Lisa Beilke
GMGlenn J. Myatt
Glenn J. Myatt

9 September 2021 in Computational Toxicology
Verified
Journal Article
Closed access
ABArianna Bassan
Arianna Bassan
VAVinicius M. Alves
Vinicius M. Alves
AAAlexander Amberg
Alexander Amberg
LALennart T. Anger
Lennart T. Anger
SAScott Auerbach
Scott Auerbach
GMGlenn J. Myatt
Glenn J. Myatt

5 April 2024 in Frontiers in Toxicology
Verified
Journal Article
Open access
ABArianna Bassan
Arianna Bassan
RSRonald Steigerwalt
Ronald Steigerwalt
DKDouglas Keller
Douglas Keller
LBLisa Beilke
Lisa Beilke
PBPaul M. Bradley
Paul M. Bradley
GMGlenn J. Myatt
Glenn J. Myatt
The ICH S1B carcinogenicity global testing guideline has been recently revised with a novel addendum that describes a comprehensive integrated Weight of Evidence (WoE) approach to determine the need for a 2-year rat carcinogenicity study. In the present work, experts from different organizations have joined efforts to standardize as much as possible a procedural framework for the integration of evidence associated with the different ICH S1B(R1) WoE criteria. The framework uses a pragmatic consensus procedure for carcinogenicity hazard assessment to facilitate transparent, consistent, and documented decision-making and it discusses best-practices both for the organization of studies and presentation of data in a format suitable for regulatory review. First, it is acknowledged that the six WoE factors described in the addendum form an integrated network of evidence within a holistic assessment framework that is used synergistically to analyze and explain safety signals. Second, the proposed standardized procedure builds upon different considerations related to the primary sources of evidence, mechanistic analysis, alternative methodologies and novel investigative approaches, metabolites, and reliability of the data and other acquired information. Each of the six WoE factors is described highlighting how they can contribute evidence for the overall WoE assessment. A suggested reporting format to summarize the cross-integration of evidence from the different WoE factors is also presented. This work also notes that even if a 2-year rat study is ultimately required, creating a WoE assessment is valuable in understanding the specific factors and levels of human carcinogenic risk better than have been identified previously with the 2-year rat bioassay alone.